Clinical Trials Logo

Retinal Degeneration clinical trials

View clinical trials related to Retinal Degeneration.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06455826 Not yet recruiting - Eye Diseases Clinical Trials

MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

Start date: June 2024
Phase: Phase 1
Study type: Interventional

A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy

NCT ID: NCT06319872 Not yet recruiting - Clinical trials for Alcohol Use Disorder

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

Start date: April 15, 2024
Phase: Phase 1
Study type: Interventional

Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder.

NCT ID: NCT06185517 Not yet recruiting - Clinical trials for Retinal Degeneration

Validation of Questionnaire in Retinal Degeneration

VQDR
Start date: January 2024
Phase: N/A
Study type: Interventional

While inherited retinal diseases are well characterized anatomically and functionally, it is also essential to understand their impact on patients' quality of life, from their ability to perform the tasks of daily living to the psychological impact of the disease on patients. Questionnaires (PRO, Patient-Reported Outcomes) are important tools for assessing this impact. However, PROs validated in French are rare, and often poorly adapted to populations with hereditary retinal degeneration. New PROs particularly adapted to retinal degeneration have recently been validated in English: the Michigan Retinal Degeneration Questionnaire (MRDQ) and the Michigan Vision-Related Anxiety Questionnaire (MVAQ). Validation of a French translation will provide a standardized, reliable tool for French-speaking patients, and enable these questionnaires to be used in gene therapy clinical trials, to assess the efficacy of treatments and their impact on patients' quality of life.